



Deficient mismatch repair and *RAS* mutation in colorectal carcinoma patients: a retrospective study in Eastern China

Xiangyan Zhang^{1,2,*}, Wenwen Ran^{1,*}, Jie Wu¹, Hong Li¹, Huamin Liu³, Lili Wang¹, Yujing Xiao¹, Xiaonan Wang¹, Yujun Li¹ and Xiaoming Xing¹

¹ Department of Pathology, Affiliated Hospital of Qingdao University, Qingdao, China

² Department of Pathology, Qingdao University Basic Medicine College, Qingdao, China

³ Department of Oncology, Affiliated Hospital of Qingdao University, Qingdao, China

* These authors contributed equally to this work.

ABSTRACT

Objectives. To investigate the frequency and prognostic role of deficient mismatch repair (dMMR) and *RAS* mutation in Chinese patients with colorectal carcinoma.

Methods. Clinical and pathological information from 813 patients were reviewed and recorded. Expression of mismatch repair proteins was tested by immunohistochemistry. Mutation analyses for *RAS* gene were performed by real-time polymerase chain reaction. Correlations of mismatch repair status and *RAS* mutation status with clinicopathological characteristics and disease survival were determined.

Results. The overall percentage of dMMR was 15.18% (121/797). The proportion of dMMR was higher in patients <50 years old ($p < 0.001$) and in the right side of the colon ($p < 0.001$). Deficient mismatch repair was also associated with mucinous production ($p < 0.001$), poor differentiation ($p < 0.001$), early tumor stage ($p < 0.05$) and bowel wall invasion ($p < 0.05$). The overall *RAS* mutation rate was 45.88%, including 42.56% (346/813) *KRAS* mutation and 3.69% (30/813) *NRAS* mutation (including three patients with mutations in both). *KRAS* mutation was significantly associated with mucinous production ($p < 0.05$), tumor stage ($p < 0.05$) and was higher in non-smokers ($p < 0.05$) and patients with a family history of colorectal carcinoma ($p < 0.05$). Overall, 44.63% (54/121) dMMR tumors harbored *KRAS* mutation, however, dMMR tumors were less likely to have *NRAS* mutation. Moreover, dMMR, *KRAS* and *NRAS* mutation were not prognostic factors for stage I–III colorectal carcinoma.

Conclusions. This study confirms that the status of molecular markers involving mismatch repair status and *RAS* mutation reflects the specific clinicopathological characteristics of colorectal carcinoma.

Subjects Gastroenterology and Hepatology, Oncology, Pathology, Medical Genetics

Keywords *KRAS* mutation, Deficient mismatch repair (dMMR), *NRAS* mutation, Prognosis, Clinicopathological characteristics, Colorectal carcinoma

INTRODUCTION

Colorectal cancer (CRC) is the fourth most common cancer in China, with 331,300 new cases and 159,300 disease-related deaths in 2012 (Chen et al., 2016). The morbidity has

Submitted 12 October 2017

Accepted 18 January 2018

Published 5 February 2018

Corresponding author
Xiaoming Xing, edithxing@126.com

Academic editor
Philip Coates

Additional Information and
Declarations can be found on
page 17

DOI 10.7717/peerj.4341

© Copyright
2018 Zhang et al.

Distributed under
Creative Commons CC-BY 4.0

OPEN ACCESS

increased steadily due to the growth of an aging population and the change of lifestyle in recent years, however, the exact mechanism and related predicted biomarkers are largely unknown.

During the past decades, microsatellite instability (MSI) and RAS mutation have been well studied as two prevalent genetic biomarkers involved in colorectal carcinogenesis. The mismatch repair (MMR) system, which includes the proteins MLH1, MSH2, MSH6 and PMS2, can repair incorrect base-pairing or unmatched DNA loops to maintain genomic stability. MSI is caused by a deficient mismatch repair (dMMR) system, which leads to a high rate of mutations in repeat sequences and accounts for approximately 15% of all CRCs as well as virtually all Lynch syndrome (LS) patients ([Geiersbach & Samowitz, 2011](#); [Marra & Boland, 1995](#); [Zhang et al., 2016](#)). Tumors with high level microsatellite instability (MSI-H) caused by germ line mutations or epigenetic silencing of MMR genes have unique clinicopathological characteristics ([Cunningham et al., 2010](#)). In early stage CRC, patients with MSI-H demonstrated favorable prognosis compared to those with low level of microsatellite instability (MSI-L) and microsatellite stability (MSS) ([Ribic et al., 2003](#); [Sinicrope et al., 2011](#)), however, these patients did not benefit from fluoropyrimidine-based adjuvant chemotherapy ([Ribic et al., 2003](#); [Sargent et al., 2010](#)).

The RAS gene family, the other significant biomarker, includes KRAS, NRAS and HRAS, and is located downstream in the epidermal growth factor receptor (EGFR) signal pathway. Mutations in the RAS gene, which are thought to occur early in the adenoma-carcinoma continuum, activate the RAS/MAPK pathway independently of EGFR activation, leading to poor response to EGFR inhibitors ([Amado et al., 2008](#); [Punt, Koopman & Vermeulen, 2016](#)). Moreover, National Comprehensive Cancer Network (NCCN) clinical practice guidelines suggested that KRAS and NRAS gene mutations should be detected for metastatic CRC (mCRC) patients before treatment with Cetuximab and Panitumumab ([Engstrom et al., 2009](#)).

The status of dMMR and RAS mutation has been widely studied in western countries. The frequency of dMMR CRCs ranged from 15–20% ([Giraldez et al., 2010](#); [Sinicrope et al., 2011](#); [Sinicrope et al., 2012](#)), KRAS mutation ranged from 20–50% ([De Roock et al., 2010](#); [Naguib et al., 2010](#); [Palomba et al., 2016](#); [Rosty, 2013](#); [Sasaki et al., 2016](#)) and NRAS mutation was noted in less than 5% ([De Roock et al., 2010](#); [Palomba et al., 2016](#); [Peeters et al., 2013](#); [Russo et al., 2014](#)). However, studies in China showed a lower frequency of dMMR compared with that in western populations, and the clinicopathological characteristics were also inconsistent ([Huang et al., 2010](#); [Jin et al., 2008](#); [Ye et al., 2015](#)). Although several studies reported the frequency of KRAS mutation in Chinese CRC patients, the number of samples was limited in most of these studies ([Shen et al., 2011](#); [Ye et al., 2015](#); [Yunxia et al., 2010](#)). Moreover, information about NRAS mutation in Chinese CRC patients was limited. Little has been studied on the association between status of dMMR and RAS mutation. Therefore, in the present study, we analyzed the dMMR and RAS mutation status of CRC patients to evaluate possible associations between dMMR, RAS mutation and the clinicopathological characteristics in primary colorectal carcinoma and we also attempted to explore the prognostic roles of dMMR and RAS mutation.




Figure 1 Consort diagram in patient selection.

Full-size  DOI: [10.7717/peerj.4341/fig-1](https://doi.org/10.7717/peerj.4341/fig-1)

MATERIALS AND METHODS

Eight hundred and thirteen formalin-fixed, paraffin-embedded tumor specimens from CRC patients who underwent primary surgical resection from 2013 to 2016 in the Affiliated Hospital of Qingdao University were selected for this study. The patients' selection method is presented in a consort diagram (Fig. 1). Patients who had undergone preoperative radiotherapy, chemotherapy and/or EGFR-targeted therapy were not included in this study.

The clinical and pathologic variables were extracted from medical records and pathological reports, which included age, gender, primary locations of tumor, tumor diameter, histological characteristics, TNM stage, smoking status, drinking status and family medication history. The patients were followed up until October 2017, and the data concerning cancer recurrence and patient survival were collected. Patients diagnosed with stage I–III colorectal carcinoma were used to explore the prognostic role of dMMR and RAS mutation with disease-free survival (DFS) and overall survival (OS).

Primary locations of tumors were divided into the right side colon (from the cecum through the transverse colon), the left side colon (from the splenic flexure through the rectosigmoid flexure) and the rectum. Tumors were staged according to the criteria of the seventh edition of the American Joint Commission on Cancer (AJCC) TNM staging system. Mucinous adenocarcinoma and signet-ring cell carcinomas were recorded as mucin-producing tumors.

The study was approved by the Ethics Committee of the Affiliated Hospital of Qingdao University (No.20130049) and all patients had signed informed consent.

Immunohistochemistry for MMR proteins

As previously described ([Lin et al., 2014b](#)), all specimens were fixed in 10% neutral buffered formalin and embedded in paraffin blocks. 3 μm -thick tissue sections were used for immunohistochemical analysis. Immunohistochemical staining was performed on an Automated Staining System (BenchMark XT, Ventana Medical Systems, Inc., Tucson, AZ, USA) according to the manufacturer's instructions. The ready-to-use antibodies were used as follows: MLH1 (No.M1, Ventana Medical Systems Inc, Tucson, AZ, USA, working solution), PMS2 (No.EPR3947, Ventana Medical Systems Inc, Arizona, USA, working solution), MSH2 (No.G219-1129, Ventana Medical Systems Inc, Tucson, AZ, USA, working solution), MSH6 (No.44, Ventana Medical Systems Inc, Tucson, AZ, USA, working solution).

The results were analyzed by two pathologists. Any tumor cell with nuclear staining was recorded as positive staining. Intact expression for all these proteins was regarded as proficient MMR (pMMR). Protein expression was defined as abnormal when nuclear staining of tumor cells was absent in the presence of positive staining in stromal cells and lymphocytes ([Fig. 2](#)). The standard criteria for diagnosis of dMMR was as follows: dMMR in MLH1: loss of MLH1 and PMS2; dMMR in MSH2: loss of MSH2 and MSH6; dMMR in MSH6: loss of MSH6; dMMR in PMS2: loss of PMS2 ([Richman, 2015](#)).

Analysis of *KRAS* and *NRAS* gene mutations by ARMS-PCR

Formalin-fixed, paraffin-embedded tumor sections were deparaffinized and air dried, and DNA was extracted using the Tiangen Blood and Tissue Kit (TiangenInc, Beijing, China). *KRAS* (codons12 and 13) and *NRAS* (codons12, 13 and 61) mutations were detected by amplification refractory mutation system in multiple quantitative polymerase chain reaction (ARMS-multi-qPCR) analysis with the Human *KRAS* and *NRAS* Mutation Detection kit (YuanQi Bio-Pharmaceutical Co., Ltd. Shanghai, China). The mutation points detected by this kit are listed in [Supplemental Information 2](#). Codons of *RAS* were amplified as described previously ([Dong et al., 2016](#)). Briefly, 3 μl sample DNA was amplified in a 25 μl reaction containing 9 μl of Mix1 and 13 μl of PCRMix3. Positive and negative controls for each sample were run simultaneously. The program for the PCR amplification flanking *KRAS* mutation site was as follows: 1 cycle at 42 °C for 5 min; 1 cycle at 94 °C for 3 min; 40 cycles at (94 °C for 15 s; 60 °C for 60 s). Fluorescence signals were collected at 60 °C. The program for the PCR amplification flanking *NRAS* mutation site was as follows: 1 cycle at 42 °C for 5 min; 1 cycle at 94 °C for 3 min; 40 cycles at (94 °C for 45 s; 60 °C for 80 s). Fluorescence signals were collected at 60 °C. The mutations were identified with a specific probe labeled with Hydroxy fluorescein (FAM). Amplicons were detected using ABI7500 Fast Real-Time PCR System (Thermo Fisher Scientific Inc., Waltham, MA, US).




Figure 2 Immunohistochemical staining for mismatch repair proteins in one case of colorectal carcinoma. Tumor cells with absent MLH1 (A) and PMS2 (B) expression, and with MSH2 (C) and MSH6 (D) expression, which were regarded as deficient MMR. Note the presence of positive staining in stromal cells and lymphocyte serving as internal positive controls.

Full-size  DOI: [10.7717/peerj.4341/fig-2](https://doi.org/10.7717/peerj.4341/fig-2)

Statistical analysis

Results were analyzed with SPSS 19.0 (SPSS, Inc, Chicago, IL, USA). For comparison of the frequencies among groups, the Chi-square test and the Fisher exact test were used. Survival curves for DFS and OS were estimated using Kaplan–Meier analysis with the log-rank test. Probability (p) value <0.05 was considered as statistical significance.

RESULTS

Patient characteristics

The main characteristics of the patients are summarized in the [Table 1](#). There were 506 (62.24%) males and 307 (37.76%) females with a mean age of 64 years. The majority of the patients (87.7%) were older than 50 years. 11.69%, 40.84%, 37.15% and 10.33% of patients presented with stage I, stage II, stage III and stage IV disease, respectively. The primary location was more common in rectum (54.49%). There were 283 (34.81%) patients with a

Table 1 Clinicopathological information of the studied patients ($n = 813$).

Characteristics	Number	(%)
Gender		
Male	506	62.24
Female	307	37.76
Age		
<50	100	12.3
≥ 50	713	87.7
Location		
Right side colon	181	22.26
Left side colon	189	23.25
Rectum	443	54.49
Mucin production		
With	133	16.36
Without	680	83.64
Tumor differentiation		
Poor	138	16.97
moderate	599	73.68
Well	33	4.06
Unknown	43	5.29
Tumor stage		
I	95	11.69
II	332	40.84
III	302	37.15
IV	84	10.33
Bowel wall invasion (T)		
T1	21	2.58
T2	104	12.79
T3	336	41.33
T4	352	43.3
Lymph node metastasis (N)		
N0	458	56.33
N1	203	24.97
N2	152	18.7
Distant metastasis (M)		
M0	729	89.67
M1	84	10.33
Lymphovascular invasion		
Yes	339	41.7
No	462	56.83
Unknown	12	1.47
Alcohol intake		
Ever	165	20.3
Never	648	79.7

(continued on next page)

Table 1 (continued)

Characteristics	Number	(%)
Smoking		
Ever	283	34.81
Never	530	65.19
Colorectal family history		
Yes	48	5.9
No	337	41.45
Unknown	428	52.65

smoking history and 165 (20.3%) patients with an alcohol in-taking history, respectively. There were 133 (16.36%) patients with mucin-productive carcinoma.

MMR status and associations with clinicopathological characteristics

MMR status was successfully evaluated in 797 patients. 121 (15.18%) patients exhibited dMMR. The rates of dMMR deficiency in MLH1, PMS2, MSH2 and MSH6 were 9.78% (78/797), 1.25% (10/797), 3.26% (26/797) and 0.87% (7/797), respectively. The rates of deficiency in MLH1/PMS2 and MSH2/MSH6 were 11.92% (88/797) and 4.14% (33/797), respectively. The association of clinicopathological characteristics with MMR status is presented in Table 2. The proportion of dMMR was higher in patients <50 years old ($p < 0.001$). A higher rate of dMMR was found in stage II cancers (19.02%, $p = 0.019$). dMMR status was also associated with mucinous production ($p < 0.001$), poor differentiation ($p < 0.001$) and localization of the tumor to the right side of the colon ($p < 0.001$). dMMR patients had a higher propensity to bowel wall invasion ($p = 0.018$).

Although dMMR tumors were present more often in patients with CRC family history, no significant difference (22.92% vs 13.13%, $p > 0.05$) was found in this study. The loss of MSH2/MSH6 expression was more often observed in patients with CRC family history (12.5% vs 3.58%, $p = 0.016$). In other respects, the patients with tumors exhibiting dMMR were similar to those exhibiting pMMR.

RAS gene mutation and associations with clinicopathological characteristics

RAS status was tested from 813 patients. The mutation rates of *KRAS* and *NRAS* were 42.56% (346/813) and 3.69% (30/813), respectively. There were three patients demonstrating mutation in both *KRAS* and *NRAS*. Patients suffering from tumors with mucinous production had a higher incidence of *KRAS* mutation compared with those having tumors without mucinous production (54.89% vs 40.18%, $p = 0.002$). A higher rate of *KRAS* mutation was found in stage II (48.49%) compared with that in stage I, stage III and stage IV (36.84%, 40.45%, 34.52%, respectively) cancers ($p = 0.023$) and in non-smokers compared with smokers (46.6% vs 34.98%, $p = 0.001$). Patients with CRC family history also showed higher rate of *KRAS* mutation (54.17% vs 37.39%, $p = 0.013$). Tumors with RAS mutation showed lower propensity to lymph node metastasis ($p = 0.006$) and distant metastasis ($p = 0.048$). No significant associations between *KRAS* mutation and other clinicopathological characteristics were found in the present study. Meanwhile,

Table 2 Correlations between mismatch repair protein deficiency and clinicopathological characteristics ($n = 797$).

Characteristics	Number	dMMR		MLH1/ PMS2		MSH2/MSH6	
		Defective (%)	<i>P</i> value	Defective (%)	<i>P</i> value	Defective (%)	<i>P</i> value
Gender							
Male	495	73 (14.75)	0.662	52 (10.51)	0.561	21 (4.24)	0.853
Female	302	48 (15.89)		36 (11.92)		12 (3.97)	
Age							
<50	99	29 (29.29)	<0.001	23 (23.23)	<0.001	6 (6.06)	0.284*
≥50	698	92 (13.18)		65 (9.31)		27 (3.87)	
Location							
Right side colon	173	61(35.26)	<0.001	43 (24.86)	<0.001	18 (10.4)	<0.001
Left side colon	185	25 (13.51)		18 (9.73)		7 (3.78)	
Rectum	439	35 (7.97)		27 (6.15)		8 (1.82)	
Mucin production							
With	131	36 (27.48)	<0.001	25 (19.08)	<0.001	11 (8.4)	0.007
Without	666	85 (12.76)		63 (9.46)		22 (3.3)	
Tumor differentiation							
Poor	134	36 (26.87)	<0.001	24 (17.91)	<0.001	12 (8.96)	0.012*
Moderate	589	71 (12.05)		51(8.66)		20 (3.39)	
Well	31	4 (12.9)		3 (9.68)		1 (3.23)	
Unknown	43						
Tumor stage							
I	94	6 (6.38)	0.019	5 (5.32)	0.110	1 (1.06)	0.288*
II	326	62 (19.02)		45 (13.81)		17 (5.21)	
III	301	41 (13.62)		30 (9.97)		11 (3.65)	
IV	76	12 (15.79)		8 (10.52)		4 (5.26)	
Bowel wall invasion (T)							
T1	20	3 (15)	0.018	2 (10)	0.139	1 (5)	0.067*
T2	102	5 (4.9)		5 (4.9)		0 (0)	
T3	334	59 (17.66)		44 (13.17)		15 (4.49)	
T4	341	54 (15.83)		37 (10.85)		17 (4.98)	
Lymph node metastasis (N)							
N0	445	74 (16.63)	0.192	54 (12.13)	0.354	20 (4.49)	0.583
N1	200	31 (15.5)		22 (11)		9 (4.5)	
N2	152	16 (10.53)		12 (7.89)		4 (2.63)	
Distant metastasis (M)							
M0	721	110 (15.26)	0.550	80 (12.13)	0.88	30 (4.16)	0.929*
M1	76	11 (14.47)		8 (10.53)		3 (3.95)	
Lymphovascular invasion							
Yes	335	47 (14.03)	0.451	35 (10.45)	0.679	12 (3.58)	0.481
No	457	73 (15.97)		52 (11.38)		21 (4.59)	
Unknown	5						

(continued on next page)

Table 2 (continued)

Characteristics	Number	dMMR		MLH1/ PMS2		MSH2/MSH6	
		Defective (%)	P value	Defective (%)	P value	Defective (%)	P value
Alcohol intake							
Ever	162	19 (11.72)	0.170	13 (8.02)	0.170	6 (3.7)	0.755
Never	635	102 (16.06)		75 (11.81)		27 (4.25)	
Smoking							
Ever	263	35 (13.31)	0.170	24 (9.13)	0.226	11 (4.18)	0.967
Never	534	86 (16.1)		64 (11.98)		22 (4.12)	
Colorectal family history							
Yes	48	11 (22.92)	0.071	5 (10.42)	0.795	6 (12.5)	0.016*
No	335	44 (13.13)		32 (9.55)		12 (3.58)	
Unknown	414						

Notes.

*Fisher's exact test was used.

NRAS mutation was not significantly associated with any clinicopathological characteristics (Table 3).

Correlations between *RAS* mutation and MMR status

RAS mutation rate was slightly higher in pMMR tumors than in dMMR tumors, but failed to reach a significant difference (46.3% vs 44.63%, $p > 0.05$). There was also no obvious correlation between MMR status and *KRAS* mutation (42.3% vs 44.63%, $p > 0.05$). No *NRAS* mutation was detected in dMMR tumors. Compared with dMMR tumors, pMMR tumors had a higher propensity to harbor *NRAS* mutation ($p = 0.009$, Table 4). The distribution of MMR and *KRAS* status is shown in Supplemental Information 3. Correlation between *KRAS* gene mutation and clinicopathological characteristics in dMMR tumors is summarized in Table 5. No significant association between *KRAS* mutation and any clinicopathological characteristics were found in dMMR tumors.

Prognostic value of dMMR and *RAS* mutation in stage I–III CRC

Of the 813 followed-up patients, 729 patients were diagnosed with stage I–III CRC, including 95 stage I patients, 332 stage II patients and 302 stage III patients. dMMR and *RAS* mutation were not prognostic for DFS and OS in stage I–III CRC (Fig. 3). Of the 121 dMMR patients, 109 patients were diagnosed with stage I–III CRC and 45.87% (50/109) patients harbored *KRAS* mutation. However, *KRAS* mutation was not prognostic factor for these patients (Fig. 4).

DISCUSSION

As prognostic and predictive biomarkers, MMR deficiency and *RAS* mutation are important for clinical treatment and prognosis of CRC patients. Compared with pMMR, patients with dMMR CRCs are reported to have unique clinicopathological characteristics such as poor differentiation, early stage, increased tumor-infiltrating lymphocytes and better clinical outcome (Brenner, Kloor & Pox, 2014; Korphaisarn et al., 2015; Ribic et al., 2003). The *RAS* gene is a predictive biomarker for the resistance to anti-EGFR monoclonal

Table 3 Correlations between RAS gene mutations and clinicopathological characteristics ($n = 813$).

Characteristics	Number	RAS		KRAS		NRAS	
		Mutation (%)	<i>P</i> value	Mutation (%)	<i>P</i> value	Mutation (%)	<i>P</i> value
Gender							
Male	506	221 (43.68)	0.105	204 (40.32)	0.097	19 (3.75)	0.9
Female	307	152 (49.51)		142 (46.25)		11 (3.58)	
Age							
<50	100	38 (38)	0.091	37 (37)	0.23	1 (1)	0.161*
≥50	713	335 (46.98)		309 (43.34)		29 (4.07)	
Location							
Right side colon	181	91 (50.28)	0.178	88 (48.62)	0.097	3 (1.66)	0.164
Left side colon	189	77 (40.74)		71 (37.57)		6 (3.17)	
Rectum	443	205 (46.28)		187 (42.21)		21 (4.74)	
Mucin production							
With	133	74 (55.64)	0.014	73 (54.89)	0.002	1 (0.75)	0.087
Without	680	299 (43.97)		273 (40.18)		29 (4.22)	
Tumor differentiation							
Poor	138	55 (39.86)	0.315	54 (39.13)	0.604	1 (0.72)	0.093
Moderate	599	276 (46.08)		251 (41.9)		28 (4.67)	
Well	33	17 (51.52)		16 (48.48)		1 (3.03)	
Unknown	43						
Tumor stage							
I	95	41 (43.16)	0.031	35 (36.84)	0.023	6 (6.32)	0.18*
II	332	170 (51.2)		161 (48.49)		9 (2.71)	
III	302	133 (44.04)		122 (40.4)		14 (4.64)	
IV	84	29 (34.52)		28 (34.52)		1 (1.19)	
Bowel wall invasion (T)							
T1	21	9 (42.86)	0.36	8 (38.1)	0.158	1 (4.76)	0.36*
T2	104	40 (38.46)		34 (32.69)		6 (5.77)	
T3	336	154 (45.83)		146 (43.45)		9 (2.68)	
T4	352	170 (48.3)		158 (44.89)		14 (3.98)	
Lymph node metastasis (N)							
N0	458	224 (48.91)	0.006	209 (45.63)	0.079	15 (3.28)	0.265
N1	203	88 (43.35)		83 (40.89)		6 (2.96)	
N2	152	61 (40.13)		54 (35.53)		9 (5.92)	
Distant metastasis (M)							
M0	729	343 (47.05)	0.048	317 (43.48)	0.116	29 (3.98)	0.353*
M1	84	30 (35.71)		29 (34.52)		1 (1.19)	
Lymphovascular invasion							
Yes	339	157 (46.31)	0.763	145 (42.77)	0.825	14 (4.13)	0.623
No	462	209 (45.24)		194 (41.99)		16 (3.46)	
Unknown	12						

(continued on next page)

Table 3 (continued)

Characteristics	Number	RAS		KRAS		NRAS	
		Mutation (%)	P value	Mutation (%)	P value	Mutation (%)	P value
Alcohol intake							
Ever	165	67 (40.61)	0.128	63 (38.18)	0.203	5 (3.03)	0.615
Never	648	306 (47.22)		283 (43.67)		25 (3.86)	
Smoking							
Ever	283	109 (38.52)	0.002	99 (34.98)	0.001	10 (3.53)	0.863
Never	530	264 (49.81)		247 (46.6)		20 (3.77)	
Colorectal family history							
Yes	48	28 (58.33)	0.017	26 (54.17)	0.013	3 (6.25)	0.178*
No	337	135 (40.95)		126 (37.39)		9 (2.67)	
Unknown	428						

Notes.

*Fisher's exact test was used.

Table 4 Correlations between mismatch repair protein deficiency and RAS status (n = 797).

MMR status	RAS		KRAS		NRAS	
	Mutant/tested cases (%)	P value	Mutant/tested cases (%)	P value	Mutant/tested cases (%)	P value
dMMR	54/121 (44.63)	0.734	54/121 (44.63)	0.635	0/121 (0)	0.009*
MHL1/PMS2 deficiency	39/88 (44.32)	0.725	39/88 (44.32)	0.875	0/88 (0)	0.044*
MSH2/MSH6 deficiency	15/33 (45.45)	0.999	15/33 (45.45)	0.72	0/33 (0)	0.391*
pMMR	313/676 (46.3)		286/676 (42.3)		30/676 (4.43)	

Notes.

*Fisher's exact test was used.

antibody (MoAb) treatment in mCRCs (*Amado et al., 2008; Punt, Koopman & Vermeulen, 2016*). However, geographic and racial differences between Chinese and other countries were reported (*Huang et al., 2010; Ismael et al., 2017; Kim et al., 2007; Vasovcak et al., 2011; Ye et al., 2015*), which need to be validated with large sample amounts. Furthermore, data regarding RAS mutation frequency and dMMR CRC is not consistent in China. Thus, we designed this study in the Chinese population aiming to explore the relationship between the RAS mutation, MMR status and clinicopathological parameters, also expecting to find some prognostic and predictive biomarkers for CRC.

Our results demonstrated an overall MMR deficiency rate of 15.18%, which is within the established range of 15–21% (*Giraldez et al., 2010; Sinicrope et al., 2012; Carethers et al., 2004; Cushman-Vokoun et al., 2013*), but slightly higher than that reported from other Chinese populations (*Huang et al., 2010; Jin et al., 2008; Ye et al., 2015*). Reports from Korea (*Jung et al., 2012*) and Japan (*Kadowaki et al., 2015*) which used PCR-based MSI testing also showed that the frequencies of MSI-H CRCs were around 10%. This discrepancy can be explained by the different detective methods to some extent. Compared with PCR-based MSI testing examination, immunohistochemistry is thought to be easily available and time-saving. Furthermore, immunohistochemistry may detect MMR-deficient cases that can be potentially missed by PCR-based MSI testing (*Shia, 2008*).

Table 5 Correlations between *KRAS* gene mutations and clinicopathological characteristics in dMMR tumors ($n = 121$).

Characteristics	Number	<i>KRAS</i> Mutation (%)	<i>P</i> value
Gender			
Male	73	31 (42.47)	0.555
Female	48	23 (47.91)	
Age			
<50	29	11 (37.93)	0.405
≥50	92	43 (46.74)	
Location			
Right side colon	61	26 (42.62)	0.891
Left side colon	25	12 (48)	
Rectum	35	16 (45.71)	
Mucin production			
With	36	20 (55.56)	0.116
Without	85	34 (40)	
Tumor differentiation			
Poor	36	10 (27.78)	0.099 [*]
Moderate	71	35 (49.3)	
Well	4	2 (50)	
Unknown	10		
Tumor stage			
I	6	2 (33.33)	0.277 [*]
II	62	33 (53.2)	
III	41	15 (36.59)	
IV	12	4 (33.33)	
Bowel wall invasion (T)			
T1	3	2 (66.67)	0.179 [*]
T2	5	0 (0)	
T3	59	26 (44.07)	
T4	54	26 (48.15)	
Lymph node metastasis (N)			
N0	74	38 (51.35)	0.056
N1	31	13 (41.94)	
N2	16	3 (18.75)	
Distant metastasis (M)			
M0	110	50 (45.45)	0.753 [*]
M1	11	4 (36.36)	
Lymphovascular invasion			
Yes	47	21 (44.68)	0.927
No	73	32 (43.83)	
Unknown	1		

(continued on next page)

Table 5 (continued)

Characteristics	Number	KRAS Mutation (%)	P value
Alcohol intake			
Ever	19	9 (47.37)	0.855
Never	102	46 (45.1)	
Smoking			
Ever	35	14 (40)	0.514
Never	86	40 (46.51)	
Colorectal family history			
Yes	11	5 (45.45)	0.589
No	44	24 (54.55)	
Unknown	66		

Notes.

*Fisher's exact test was used.

Correlations between dMMR status and clinicopathological characteristics were controversial (*Ismael et al., 2017; Jin et al., 2008; Ribic et al., 2003; Sinicrope et al., 2011*). Reports from three independent Chinese groups (*Huang et al., 2010; Jin et al., 2008; Ye et al., 2015*) indicated that dMMR had specific associations such as female gender, right sided colon tumors and mucinous tumors. In a study including 1,063 CRCs, *Lin et al. (2014a)* observed that MSI was associated not only with gender, tumor location and mucin production, but also with tumor differentiation and tumor stage. In our current study, we found patients younger than 50 tended to be dMMR. These diverse findings may be attributed to different criteria for age division, ethnicities, environmental factors as well as the specificity and sensitivity of the detection methods.

In our study, there was a correlation between MSH2/MSH6 deficiency and family history of CRC, but not MLH1/PMS2 deficiency. In addition, according to the Bethesda criteria (*Burt et al., 2010*), 12 CRCs were diagnosed with LS. In MSH2/MSH6 deficient CRCs, 33.3% (6/18) were LS, while in MLH1/PMS2 defective cases, 13.95% (6/43) were LS, suggesting MSH2/MSH6 deficient patients had higher opportunity to be diagnosed with LS. Some of the recent studies may help to explain this finding: the majority dMMR CRCs were caused by inactivation of MLH1 and more than 70% MLH1 deficiency was caused by *MLH1* promoter hypermethylation (*Hampel et al., 2005*), which could distinguish sporadic dMMR CRCs from LS cases, therefore, most MLH1 defective tumors were sporadic CRC. Another interesting phenomenon in our investigation is that we found most patients' family medical history was unclear and they did not know whether other family members had polyps removed, moreover, many cancers might be prevented by early stage colonoscopy, so the family history may be deceptive (*Hampel, 2014*). Therefore, screening strategy based on family history may be improper. All patients with newly diagnosed CRC should be screened for LS (*Hampel, 2014*). Inconsistent with previous studies, which indicated that patients with dMMR tumors had significantly better survival than that of pMMR patients (*Des Guetz et al., 2009; Korphaisarn et al., 2015; Lanza et al., 2006*), our study showed that dMMR was not a prognostic factor for patients with stage I–III CRC, although the incidence of dMMR




Figure 3 Survival curves for disease free survival (DFS) and overall survival (OS) in stage I–III colorectal carcinoma according to dMMR or RAS status. (A) Disease free survival (DFS) according to dMMR status; (B) overall survival (OS) according to dMMR status; (C) DFS according to KRAS status; (D) OS according to KRAS status; (E) DFS according to NRAS status; (F) OS according to NRAS status.

Full-size [DOI: 10.7717/peerj.4341/fig-3](https://doi.org/10.7717/peerj.4341/fig-3)

in stage III disease was lower, suggesting that dMMR tumors had lower propensity to metastasize.

In the present study, the mutation rates of *KRAS* and *NRAS* are 42.56% and 3.69%, respectively. The *KRAS* mutation rate is significantly higher than the value of 20.7% among 314 CRC patients from Taiwan, China (Liou et al., 2011), 22% among 202 CRC patients from the England (Naguib et al., 2010), 30.1% among 392 CRC patients from Switzerland (Zlobec et al., 2010), but similar to that previously reported in Guangzhou, China (43.9%, 25/57) (Mao et al., 2012). Several factors may lead to such differences, such as sample size,




Figure 4 Survival curves for disease free survival (DFS) and overall survival (OS) in stage I–III dMMR colorectal carcinoma according to KRAS status. (A) Disease free survival (DFS) according to KRAS status; (B) overall survival (OS) according to KRAS status.

Full-size [DOI: 10.7717/peerj.4341/fig-4](https://doi.org/10.7717/peerj.4341/fig-4)

dietary and lifestyle factors, as well as racial and/or environmental differences. Furthermore, we detected the coding sequence of codon12 and codon13 in exon 2 of the *KRAS* gene, which may help to explain the higher percentage of *KRAS* mutation than those detected in codon12 only. Except for exon 2, recent studies have shown 5–10% of tumors harbored exon 3 or exon 4 mutation (Janakiraman *et al.*, 2010; Lin *et al.*, 2014a), which would also result in resistance to anti-EGFR inhibitors. Therefore, extending the detection spectrum of *RAS* might help to optimize the selection of the CRC patients to receive anti-EGFR MoAbs.

The frequency of *KRAS* mutation has been reported to be associated with age, gender, differentiation and tumor stage (Gao *et al.*, 2012; Li *et al.*, 2011; Ye *et al.*, 2015; Yunxia *et al.*, 2010; Zhu *et al.*, 2012). Inconsistent with these results, our study showed that *KRAS* mutation was associated with mucin production, tumor stage, non-smoking and CRC family history. *RAS* mutated tumors showed lower propensity to lymph node and distant metastasis. No convincing evidence demonstrates that *KRAS* mutation is an independent prognostic factor for CRC (Jin *et al.*, 2008; Palomba *et al.*, 2016; Russo *et al.*, 2014; Yunxia *et al.*, 2010). In the present study, no associations of *KRAS* mutation with DFS and OS were found in patients with stage I–III CRC. Further studies based on longer follow-up time and larger sample size are needed to confirm this conclusion.

In our study, the percentage of the four tumor subgroups, including dMMR/*KRAS* mutation, dMMR/*KRAS* wild-type, pMMR/*KRAS* mutation and pMMR/*KRAS* wild-type tumors was 6.78%, 8.4%, 35.88%, 48.94%, respectively, which is similar to the data reported by a study from Beijing, China (Ye *et al.*, 2015). According to recent reports (Nash *et al.*, 2009; Roth *et al.*, 2010), patients with a MSS/*KRAS* mutant tumor had the worst survival than the other three groups. Therefore, dMMR and *KRAS* markers may provide a foundation for developing a molecular prognostic scoring system for CRC patients in the future.

Previous studies have shown that pMMR patients tended to harbor more *KRAS* mutation than dMMR patients (Naguib *et al.*, 2010; Ye *et al.*, 2015). One hypothesis for this result

is that *BRAF* and *KRAS* mutations were almost mutually exclusive in CRC and MSI tumors are more likely to harbor a *BRAF* mutation, so MSS tumors might harbor more *KRAS* mutations ([Naguib et al., 2010](#)). However, in the present study, we did not find any differences in *KRAS* mutation between pMMR and dMMR tumors, and further studies based on larger sample size are needed to explore this controversy in Chinese CRCs.

Additionally, our study provided an opportunity to investigate the status of *KRAS* mutation in Chinese dMMR patients. *KRAS* mutation presented in 44.63% dMMR patients in our study, similar to previous studies in western countries ([Cushman-Vokoun et al., 2013](#); [Oliveira, 2004](#)). All of these results indicate that *KRAS* mutation could be quite common in dMMR tumors. There were no associations between *KRAS* mutation and clinicopathologic characteristics in dMMR tumors. A study conducted by [Nash et al. \(2009\)](#) indicated that *KRAS* status was an independent prognostic factor in early stage MSI CRC patients. Moreover, MSI patients with wild-type *KRAS* and *BRAF* tumors have more favorable prognosis than patients with mutated *KRAS* or *BRAF* tumors in early stage CRC ([De Cuba et al., 2016](#); [Phipps et al., 2015](#)). However, we did not find *KRAS* mutation as a prognostic factor for dMMR patients with stage I–III CRC.

NRAS, as one of the *RAS* family, showed close relations with *KRAS*. Unlike *KRAS*, *NRAS* mutation was rarely detected in CRC patients. In our study, the mutation rate of *NRAS* was 3.69%, similar to previous reports ([Chang et al., 2016](#); [Irahara et al., 2010](#); [Palomba et al., 2016](#); [Peeters et al., 2013](#)). Moreover, we observed 25/388 *KRAS* wild-type tumors with *NRAS* mutation, which can partially help to explain the resistance to anti-EGFR MoAb in some *KRAS* wild-type patients. Considering the heavy financial burden in MoAb treatment in CRC patients, *NRAS* mutation should be tested before MoAb treatment in *KRAS* wild-type tumors. Another interesting phenomenon is that no *NRAS* mutation was detected in dMMR patients, which suggested *NRAS* mutation might be mutually exclusive with dMMR. Meanwhile, *NRAS* mutation was not significantly associated with any clinicopathologic characteristics in our study.

However, our results should be elucidated with consideration of its limitations: first, the sample size was relatively small, rendering some findings inconclusive; second, we used a commercially available kit authenticated by China Food and Drug Administration (CFDA) and the mutation subgroups were uncertain. A study conducted by [Lin et al. \(2014a\)](#) demonstrated that mutation in *KRAS* codon12 was associated with significantly poorer outcome than mutations elsewhere or wild-type *KRAS*. Therefore, the subgroup of mutation codons should be carefully explored in future; third, we did not collect data of clinical management, therefore, the influence of clinical treatment for survival was uncertain.

CONCLUSION

In conclusion, this was an exploratory analysis of correlations between *RAS* mutation and MMR status with clinicopathological characteristics in Eastern Chinese CRC patients. The status of these molecular markers, involving MLH1/PMS2, MSH2/MSH6, *KRAS* and

NRAS mutation, reflects the specific clinicopathological characteristics of CRC. More comprehensive molecular classification and survival analysis should be explored in future experiments.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

The present study was supported by grants from the National Natural Science Foundation of China (nos. 81201947), the Natural Science Foundation of Shandong, China (ZR2009CM014), and the Excellent Young Scientist Foundation of Shandong Province, China (no. 2006BSB14001), Qingdao minsheng science and technology project (no.17-3-3-38-nsh). There was no additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:

National Natural Science Foundation of China: 81201947.

Natural Science Foundation of Shandong, China: ZR2009CM014.

Excellent Young Scientist Foundation of Shandong Province, China: 2006BSB14001.

Qingdao minsheng science and technology project: 17-3-3-38-nsh.

Competing Interests

The authors declare there are no competing interests.

Author Contributions

- Xiangyan Zhang conceived and designed the experiments, performed the experiments, wrote the paper.
- Wenwen Ran conceived and designed the experiments, performed the experiments, contributed reagents/materials/analysis tools, wrote the paper.
- Jie Wu performed the experiments, reviewed drafts of the paper.
- Hong Li contributed reagents/materials/analysis tools.
- Huamin Liu reviewed drafts of the paper.
- Lili Wang analyzed the data.
- Yujing Xiao prepared figures and/or tables.
- Xiaonan Wang conceived and designed the experiments, performed the experiments, prepared figures and/or tables.
- Yujun Li analyzed the data, prepared figures and/or tables.
- Xiaoming Xing conceived and designed the experiments, contributed reagents/materials/analysis tools, wrote the paper, reviewed drafts of the paper.

Human Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

The study was approved by the Ethics Committee of the Affiliated Hospital of Qingdao University. Approval number: No.QDFY-20130049.

Data Availability

The following information was supplied regarding data availability:

The raw data has been provided in the [Supplemental Files](#).

Supplemental Information

Supplemental information for this article can be found online at <http://dx.doi.org/10.7717/peerj.4341#supplemental-information>.

REFERENCES

- Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. 2008. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *Journal of Clinical Oncology* 26:1626–1634 DOI 10.1200/JCO.2007.14.7116.
- Brenner H, Kloor M, Pox CP. 2014. Colorectal cancer. *Lancet* 383:1490–1502 DOI 10.1016/s0140-6736(13)61649-9.
- Burt RW, Barthel JS, Dunn KB, David DS, Drelichman E, Ford JM, Giardiello FM, Gruber SB, Halverson AL, Hamilton SR, Ismail MK, Jasperson K, Lazenby AJ, Lynch PM, Martin EW, Mayer Jr RJ, Ness RM, Provenzale D, Rao MS, Shike M, Steinbach G, Terdiman JP, Weinberg D. 2010. NCCN clinical practice guidelines in oncology. Colorectal cancer screening. *Journal of the National Comprehensive Cancer Network* 8:8–61.
- Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, Cabrera BL, Goel A, Arnold CA, Miyai K, Boland CR. 2004. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. *Gastroenterology* 126:394–401 DOI 10.1053/j.gastro.2003.12.023.
- Chang YY, Lin PC, Lin HH, Lin JK, Chen WS, Jiang JK, Yang SH, Liang WY, Chang SC. 2016. Mutation spectra of RAS gene family in colorectal cancer. *American Journal of Surgery* 212:537–544 DOI 10.1016/j.amjsurg.2016.02.013.
- Chen W, Zheng R, Zuo T, Zeng H, Zhang S, He J. 2016. National cancer incidence and mortality in China, 2012. *Chinese Journal of Cancer Research* 28:1–11 DOI 10.3978/j.issn.1000-9604.2016.02.08.
- Cunningham D, Atkin W, Lenz H-J, Lynch HT, Minsky B, Nordlinger B, Starling N. 2010. Colorectal cancer. *Lancet* 375:1030–1047 DOI 10.1016/S0140-6736(10)60353-4.
- Cushman-Vokoun AM, Stover DG, Zhao Z, Koehler EA, Berlin JD, Vnencak-Jones CL. 2013. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing. *Clinical Colorectal Cancer* 12:168–178 DOI 10.1016/j.clcc.2013.04.005.
- De Cuba EMV, Snaebjornsson P, Heideman DAM, Van Grieken NCT, Bosch LJW, Finjeman RJA, Belt E, Bril H, Stockmann HBAC, Hooijberg E, Punt CJA, Koopman

- M, Nagtegaal ID, Coupé VHM, Carvalho B, Meijer GA. 2016. Prognostic value of *BRAF* and *KRAS* mutation status in stage II and III microsatellite instable colon cancers. *International Journal of Cancer* 138:1139–1145 DOI 10.1002/ijc.29855.
- De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilias G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. 2010. Effects of *KRAS*, *BRAF*, *NRAS*, and *PIK3CA* mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *The Lancet Oncology* 11:753–762 DOI 10.1016/s1470-2045(10)70130-3.
- Des Guetz G, Schischmanoff O, Nicolas P, Perret G-Y, Morere J-F, Uzzan B. 2009. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. *European Journal of Cancer* 45:1890–1896 DOI 10.1016/j.ejca.2009.04.018.
- Dong YU, Ren W, Qi J, Jin BO, Li Y, Tao H, Xu R, Li Y, Zhang Q, Han B. 2016. EGFR, ALK, RET, *KRAS* and *BRAF* alterations in never-smokers with non-small cell lung cancer. *Oncology Letters* 11:2371–2378 DOI 10.3892/ol.2016.4235.
- Engstrom AF, Arnoletti JP, ABB III, Chen Y-J, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. 2009. The NCCN colon cancer clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network* 7:778–831.
- Gao J, Sun ZW, Li YY, Shen L. 2012. Mutations of *KRAS* and *BRAF* in Chinese patients with colorectal carcinoma: analyses of 966 cases. *Zhonghua Bing Li Xue Za Zhi* 41:579–583 [In Chinese] DOI 10.3760/cma.j.issn.0529-5807.2012.09.002.
- Geiersbach KB, Samowitz WS. 2011. Microsatellite instability and colorectal cancer. *Archives of Pathology and Laboratory Medicine* 135:1269–1277 DOI 10.5858/arpa.2011-0035-RA.
- Giraldez MD, Balaguer F, Bujanda L, Cuatrecasas M, Munoz J, Alonso-Espinaco V, Larzabal M, Petit A, Gonzalo V, Ocana T, Moreira L, Enriquez-Navascues JM, Boland CR, Goel A, Castells A, Castellvi-Bel S. 2010. MSH6 and MUTYH deficiency is a frequent event in early-onset colorectal cancer. *Clinical Cancer Research* 16:5402–5413 DOI 10.1158/1078-0432.CCR-10-1491.
- Hampel H. 2014. NCCN increases the emphasis on genetic/familial high-risk assessment in colorectal cancer. *Journal of the National Comprehensive Cancer Network* 12:829–831 DOI 10.6004/jnccn.2014.0200.
- Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Nakagawa H, Sotamaa K, Prior TW, Westman J, Panescu J, Fix D, Lockman J, Comeras

- I, De la Chapelle A. 2005. Screening for the Lynch syndrome (hereditary non-polyposis colorectal cancer). *New England Journal of Medicine* 352:1851–1860 DOI 10.1056/NEJMoa043146.
- Huang YQ, Yuan Y, Ge WT, Hu HG, Zhang SZ, Zheng S. 2010. Comparative features of colorectal and gastric cancers with microsatellite instability in Chinese patients. *Journal of Zhejiang University Science B* 11:647–653 DOI 10.1631/jzus.B1000198.
- Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, Iafrate AJ, Fuchs CS, Haigis KM, Oginio S. 2010. NRAS mutations are rare in colorectal cancer. *Diagnostic Molecular Pathology* 19:157–163 DOI 10.1097/PDM.0b013e3181c93fd1.
- Ismael NEHS, El Sheikh SA, Talaat SM, Salem EM. 2017. Mismatch repair proteins and microsatellite instability in colorectal carcinoma (MLH1, MSH2, MSH6 and PMS2): histopathological and immunohistochemical study. *Open Access Macedonian Journal of Medical Sciences* 5:9–13 DOI 10.3889/oamjms.2017.003.
- Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, Halilovic E, Wilson M, Huberman K, Ricarte Filho JC, Persaud Y, Levine DA, Fagin JA, Jhanwar SC, Mariadason JM, Lash A, Ladanyi M, Saltz LB, Heguy A, Paty PB, Solit DB. 2010. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. *Cancer Research* 70:5901–5911 DOI 10.1158/0008-5472.can-10-0192.
- Jin HY, Liu X, Li VK, Ding Y, Yang B, Geng J, Lai R, Ding S, Ni M, Zhao R. 2008. Detection of mismatch repair gene germline mutation carrier among Chinese population with colorectal cancer. *BMC Cancer* 8:44 DOI 10.1186/1471-2407-8-44.
- Jung SB, Lee HI, Oh HK, Shin IH, Jeon CH. 2012. Clinico-pathologic parameters for prediction of microsatellite instability in colorectal cancer. *Cancer Research and Treatment* 44:179–186 DOI 10.4143/crt.2012.44.3.179.
- Kadowaki S, Kakuta M, Takahashi S, Takahashi A, Arai Y, Nishimura Y, Yatsuoka T, Ooki A, Yamaguchi K, Matsuo K, Muro K, Akagi K. 2015. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. *World Journal of Gastroenterology* 21:1275–1283 DOI 10.3748/wjg.v21.i4.1275.
- Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N, Allegra CJ, National Cancer Institute. 2007. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. *Journal of Clinical Oncology* 25:767–772 DOI 10.1200/JCO.2006.05.8172.
- Korphaisarn K, Pongpaibul A, Limwongse C, Roothumnong E, Klaisuban W, Nimmannit A, Jinawath A, Akewanlop C. 2015. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer. *World Journal of Gastroenterology* 21:926–934 DOI 10.3748/wjg.v21.i3.926.
- Lanza G, Gafa R, Santini A, Maestri I, Guerzoni L, Cavazzini L. 2006. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. *Journal of Clinical Oncology* 24:2359–2367 DOI 10.1200/jco.2005.03.2433.

- Li HT, Lu YY, An YX, Wang X, Zhao QC. 2011. *KRAS*, *BRAF* and *PIK3CA* mutations in human colorectal cancer: relationship with metastatic colorectal cancer. *Oncology Reports* 25:1691–1697 DOI 10.3892/or.2011.1217.
- Lin C-C, Lin J-K, Lin T-C, Chen W-S, Yang S-H, Wang H-S, Lan Y-T, Jiang J-K, Yang M-H, Chang S-C. 2014a. The prognostic role of microsatellite instability, codon-specific *KRAS*, and *BRAF* mutations in colon cancer. *Journal of Surgical Oncology* 110:451–457 DOI 10.1002/jso.23675.
- Lin S, YuJun L, XiaoMing X, WenWen R. 2014b. Expression and significance of leptin receptor, p-STAT3 and p-AKT in diffuse large B-cell lymphoma. *Acta Histochemica* 116:126–130 DOI 10.1016/j.acthis.2013.06.003.
- Liou JM, Wu MS, Shun CT, Chiu HM, Chen MJ, Chen CC, Wang HP, Lin JT, Liang JT. 2011. Mutations in *BRAF* correlate with poor survival of colorectal cancers in Chinese population. *International Journal of Colorectal Disease* 26:1387–1395 DOI 10.1007/s00384-011-1229-1.
- Mao C, Zhou J, Yang Z, Huang Y, Wu X, Shen H, Tang J, Chen Q. 2012. *KRAS*, *BRAF* and *PIK3CA* mutations and the loss of *PTEN* expression in Chinese patients with colorectal cancer. *PLOS ONE* 7:e36653 DOI 10.1371/journal.pone.0036653.t001.
- Marra G, Boland CR. 1995. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. *Journal of the National Cancer Institute* 87:1114–1125.
- Naguib A, Mitrou PN, Gay LJ, Cooke JC, Luben RN, Ball RY, McTaggart A, Arends MJ, Rodwell SA. 2010. Dietary, lifestyle and clinicopathological factors associated with *BRAF* and *K-ras* mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. *BMC Cancer* 10:99 DOI 10.1186/1471-2407-10-99.
- Nash GM, Gimbel M, Cohen AM, Zeng Z-S, Ndubuisi MI, Nathanson DR, Ott J, Barany F, Paty PB. 2009. *KRAS* mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. *Annals of Surgical Oncology* 17:416–424 DOI 10.1245/s10434-009-0713-0.
- Oliveira C. 2004. Distinct patterns of *KRAS* mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. *Human Molecular Genetics* 13:2303–2311 DOI 10.1093/hmg/ddh238.
- Palomba G, Doneddu V, Cossu A, Paliogiannis P, Manca A, Casula M, Colombino M, Lanzillo A, Defraia E, Pazzola A, Sanna G, Putzu C, Ortu S, Scartozzi M, Ionta MT, Baldino G, Sarobba G, Capelli F, Sedda T, Viridis L, Barca M, Gramignano G, Budroni M, Tanda F, Palmieri G. 2016. Prognostic impact of *KRAS*, *NRAS*, *BRAF*, and *PIK3CA* mutations in primary colorectal carcinomas: a population-based study. *Journal of Translational Medicine* 14:Article 292 DOI 10.1186/s12967-016-1053-z.
- Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, Huang J, Humblet Y, Van Laethem JL, Andre T, Wiezorek J, Reese D, Patterson SD. 2013. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. *Clinical Cancer Research* 19:1902–1912 DOI 10.1158/1078-0432.CCR-12-1913.

- Phipps AI, Limburg PJ, Baron JA, Burnett-Hartman AN, Weisenberger DJ, Laird PW, Sinicrope FA, Rosty C, Buchanan DD, Potter JD, Newcomb PA. 2015.** Association between molecular subtypes of colorectal cancer and patient survival. *Gastroenterology* **148**:77–87 DOI [10.1053/j.gastro.2014.09.038](https://doi.org/10.1053/j.gastro.2014.09.038).
- Punt CJA, Koopman M, Vermeulen L. 2016.** From tumour heterogeneity to advances in precision treatment of colorectal cancer. *Nature Reviews Clinical Oncology* **14**:235–246 DOI [10.1038/nrclinonc.2016.171](https://doi.org/10.1038/nrclinonc.2016.171).
- Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S. 2003.** Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. *New England Journal of Medicine* **349**:247–257 DOI [10.1056/NEJMoa022289](https://doi.org/10.1056/NEJMoa022289).
- Richman S. 2015.** Deficient mismatch repair: read all about it (Review). *International Journal of Oncology* **47**:1189–1202 DOI [10.3892/ijo.2015.3119](https://doi.org/10.3892/ijo.2015.3119).
- Rosty C, Young JP, Walsh MD, Clendenning M, Walters RJ, Pearson S, Pavluk E, Nagler B, Pakenas D, Jass JR, Jenkins MA, Win AK, Southey MC, Parry S, Hopper JL, Giles GG, Williamson E, English DR, Buchanan DD. 2013.** Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. *Modern Pathology* **26**:825–834 DOI [10.1038/modpathol.2012.240](https://doi.org/10.1038/modpathol.2012.240).
- Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F. 2010.** Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. *Journal of Clinical Oncology* **28**:466–474 DOI [10.1200/JCO.2009.23.3452](https://doi.org/10.1200/JCO.2009.23.3452).
- Russo AL, Borger DR, Szymonifka J, Ryan DP, Wo JY, Blaszkowsky LS, Kwak EL, Allen JN, Wadlow RC, Zhu AX, Murphy JE, Faris JE, Dias-Santagata D, Haigis KM, Ellisen LW, Iafrate AJ, Hong TS. 2014.** Mutational analysis and clinical correlation of metastatic colorectal cancer. *Cancer* **120**:1482–1490 DOI [10.1002/cncr.28599](https://doi.org/10.1002/cncr.28599).
- Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S. 2010.** Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. *Journal of Clinical Oncology* **28**:3219–3226 DOI [10.1200/JCO.2009.27.1825](https://doi.org/10.1200/JCO.2009.27.1825).
- Sasaki Y, Akasu T, Saito N, Kojima H, Matsuda K, Nakamori S, Komori K, Amagai K, Yamaguchi T, Ohue M, Nagashima K, Yamada Y. 2016.** Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancer. *Cancer Science* **107**:1006–1012 DOI [10.1111/cas.12950](https://doi.org/10.1111/cas.12950).
- Shen H, Yuan Y, Hu HG, Zhong X, Ye XX, Li MD, Fang WJ, Zheng S. 2011.** Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. *World Journal of Gastroenterology* **17**:809–816 DOI [10.3748/wjg.v17.i6.809](https://doi.org/10.3748/wjg.v17.i6.809).
- Shia J. 2008.** Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer

- syndrome. Part I. The utility of immunohistochemistry. *Journal of Molecular Diagnostics* **10**:293–300 DOI [10.2353/jmoldx.2008.080031](https://doi.org/10.2353/jmoldx.2008.080031).
- Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ. 2011.** DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. *Journal of the National Cancer Institute* **103**:863–875 DOI [10.1093/jnci/djr153](https://doi.org/10.1093/jnci/djr153).
- Sinicrope FA, Foster NR, Yoon HH, Smyrk TC, Kim GP, Allegra CJ, Yothers G, Nikcevic DA, Sargent DJ. 2012.** Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. *Journal of Clinical Oncology* **30**:406–412 DOI [10.1200/JCO.2011.39.2563](https://doi.org/10.1200/JCO.2011.39.2563).
- Vasovcak P, Pavlikova K, Sedlacek Z, Skapa P, Kouda M, Hoch J, Krepelova A. 2011.** Molecular genetic analysis of 103 sporadic colorectal tumours in Czech patients. *PLOS ONE* **6**:e24114 DOI [10.1371/journal.pone.0024114](https://doi.org/10.1371/journal.pone.0024114).
- Ye JX, Liu Y, Qin Y, Zhong HH, Yi WN, Shi XY. 2015.** *KRAS* and *BRAF* gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients. *World Journal of Gastroenterology* **21**:1595–1605 DOI [10.3748/wjg.v21.i5.1595](https://doi.org/10.3748/wjg.v21.i5.1595).
- Yunxia Z, Jun C, Guanshan Z, Yachao L, Xueke Z, Jin L. 2010.** Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer. *BMC Medical Genetics* **11**:34 DOI [10.1186/1471-2350-11-34](https://doi.org/10.1186/1471-2350-11-34).
- Zhang C-M, Lv J-F, Gong L, Yu L-Y, Chen X-P, Zhou H-H, Fan L. 2016.** Role of deficient mismatch repair in the personalized management of colorectal cancer. *International Journal of Environmental Research and Public Health* **13**:Article 892 DOI [10.3390/ijerph13090892](https://doi.org/10.3390/ijerph13090892).
- Zhu XL, Cai X, Zhang L, Yang F, Sheng WQ, Lu YM, Du X, Zhou XY. 2012.** *KRAS* and *BRAF* gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese. *Zhonghua Bing Li Xue Za Zhi* **41**:584–589 [In Chinese] DOI [10.3760/cma.j.issn.0529-5807.2012.09.003](https://doi.org/10.3760/cma.j.issn.0529-5807.2012.09.003).
- Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A. 2010.** Clinicopathological and protein characterization of *BRAF*- and K-RAS-mutated colorectal cancer and implications for prognosis. *International Journal of Cancer* **127**:367–380 DOI [10.1002/ijc.25042](https://doi.org/10.1002/ijc.25042).